Mabpharm Ltd. has announced its unaudited consolidated financial results for the six months ended June 30, 2025. The company reported a significant increase in revenue, achieving RMB 274.183 million compared to RMB 108.483 million for the same period in 2024, marking a 152.7% growth. The gross profit also saw a substantial rise, reaching RMB 241.245 million from RMB 94.356 million, reflecting a 155.7% increase. The company's selling and distribution expenses increased to RMB 163.246 million from RMB 69.6 million, growing by 134.5%. Research and development expenses decreased by 57.7%, totaling RMB 23.809 million compared to RMB 56.293 million in the previous year. Administrative expenses were reduced by 15.3%, amounting to RMB 51.366 million. Mabpharm Ltd. reported a profit before tax of RMB 2.898 million, a significant turnaround from a loss of RMB 97.569 million in the previous year, marking a change of 103.0%. The profit and total comprehensive income for the period was also RMB 2.898 million, compared to a loss of RMB 97.569 million in the same period in 2024. In terms of future outlook, Mabpharm Ltd. plans to leverage its efficient sales system and focus on niche markets to benefit from the ongoing pharmaceutical reform in China. The company sees significant opportunities arising from the restructuring of the pharmaceutical market, driven by the new Medical Insurance policy and central procurement negotiations. This trend is expected to enhance market penetration and drive the development of the pharmaceutical sector.